Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma

Cancer Gene Therapy

Volumn 12, Issue 7, 2005, Pages 608-616

  Okada, Yuka ^a   Okada, Naoki ^b   Mizuguchi, Hiroyuki ^c   Hayakawa, Takao ^c   Nakagawa, Shinsaku ^d   Mayumi, Tadanori ^d  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; Hepatotoxicity; Melanoma; Suicide gene therapy; Tissue specific promoter

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; ENZYME; GANCICLOVIR; MONOPHENOL MONOOXYGENASE; TELOMERASE; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG SAFETY; ENZYME BLOOD LEVEL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER TOXICITY; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROMOTER REGION; SAFETY; SUICIDE GENE THERAPY; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS MUTANT; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALS; BODY WEIGHT; DNA-BINDING PROTEINS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MONOPHENOL MONOOXYGENASE; OLIGOPEPTIDES; PROMOTER REGIONS (GENETICS); SIMPLEXVIRUS; SKIN NEOPLASMS; TELOMERASE; THYMIDINE KINASE; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; CYTOMEGALOVIRUS; MURINAE; SIMPLEXVIRUS;

EID: 22044453075     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700824     Document Type: Article

References (37)

1. Schadendorf D. Gene-based therapy of malignant melanoma. Semin Oncol. 2002;29:503-512.
2. Prehn RT. The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma. Cancer Res. 1996;56:937-940.
3. Wildemore IV JK, Schuchter L, Mick R, et al. Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann Plast Surg. 2001;46:488-494.
4. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993;53:83-88.
5. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-1092.
6. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther. 1998;9:2595-2604.
7. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther. 1999;10:2325-2335.
8. Morris JC, Ramsey WJ, Wildner O, et al. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther. 2000;11:487-503.
9. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13-26.
10. Okada T, Caplen NJ, Ramsey WJ, et al. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo. J Gene Med. 2004;6:288-299.
11. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
12. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000;60:3989-3999.
13. Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K. Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. Int J Oncol. 2003;23:1309-1315.
14. Okada Y, Okada N, Nakagawa S, et al. Tumor necrosis factor α-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors. Jpn J Cancer Res. 2002;93:436-444.
15. Okada Y, Okada N, Nakagawa S, et al. Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Lett. 2002;177:57-63.
16. Okada Y, Okada N, Mizuguchi H, et al. Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim Biophys Acta. 2004;1670:172-180.
17. Mizuguchi H, Hayakawa T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther. 2002;9:236-242.
18. Okada Y, Okada N, Mizuguchi H, Hayakawa T, Mayumi T, Mizuno N. An investigation of adverse effects caused by the injection of high-dose TNFα-expressing adenovirus vector into established murine melanoma. Gene Therapy. 2003;10:700-705.
19. van der, Eb MM, Cramer SJ, Vergouwe Y, et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy. 1998;5:451-458.
20. Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Therapy. 1998;5:1363-1371.
21. Bustos M, Sangro B, Alzuguren P, et al. Liver damage using suicide genes. A model for oval cell activation. Am J Pathol. 2000;157:549-559.
22. Hearing VJ, Jimenez M. Analysis of mammalian pigmentation at the molecular level. Pigment Cell Res. 1989;2:75-85.
23. Hearing VJ, Tsukamoto K. Enzymatic control of pigmentation in mammals. FASEB J. 1991;5:2902-2909.
24. Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000;60:5359-5364.
25. Koga S, Hirohata S, Kondo Y, et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther. 2000;11:1397-1406.
26. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Therapy. 2002;9:30-37.
27. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003;63:3181-3188.
28. Kolquist KA, Ellisen LW, Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998;19:182-186.
29. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999;59:551-557.
30. Braunstein I, Cohen-Barak O, Shachaf C, et al. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. Cancer Res. 2001;61:5529-5536.
31. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 1998;9:2577-2583.
32. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther. 1999;10:2013-2017.
33. Mizuguchi H, Koizumi N, Hosono T, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Therapy. 2001;8:730-735.
34. Park BJ, Brown CK, Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther. 1999;10:889-898.
35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
36. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther. 1998;9:2363-2373.
37. McCart JA, Wang ZH, Xu H, et al. Development of a melanoma-specific adenovirus. Mol Ther. 2002;6:471-480.